The Institutional Biosafety Committee (IBC) is a standing committee and is responsible for reviewing all University research and teaching activities conducted by faculty, staff, students and/or visiting scientists on University property that involve the use of biological agents. Biological agents are defined as microorganisms, Recombinant or Synthetic Nucleic Acid Molecules experiments as defined by NIH Guidelines, materials derived from human and non-human primates, or biological toxins.
The mission of the IBC is to ensure that all activities involving biological agents and the facilities used to conduct such work are in compliance with all external regulations, and applicable University policies.
The committee will function to ensure that investigators handle biological agents in a safe and responsible manner, and meet criteria as described by the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules; the CDC/NIH publication Biosafety in the Microbiological and Biomedical Laboratories; applicable regulations defined by the Virginia Department of Environmental Quality; the OSHA Bloodborne Pathogens Standard; HHS and USDA final rules for the possession, use, and transfer of select agents and toxins; and other applicable requirements. Foremost, the IBC's objective shall be to ensure that such activities meet the standards of good biological safety practice emphasizing protection of personnel, the public and the environment.
The IBC shall assist principal investigators and protocol directors in meeting their responsibilities; impose requirements; and review and approve policies, proposals, procedures, programs, and facilities pursuant to the safe and legally compliant use of biological agents.
If you would like to attend a meeting, please contact Paul Skoglund at firstname.lastname@example.org or 434-243-0726, by the date the Registration Documents are due.
|Date of IBC Meeting||Date Registration (IAR) Documents are due||Location||Time|
|January 5th, 2021||December 21st, 2020||MR6, room 2501||8:30am|
|February 2nd, 2021||January 21st, 2021||MR6, room 2501||8:30am|
|March 2nd, 2021||February 18th, 2021||MR6, room 2501||8:30am|
|April 6th, 2021||March 25th, 2021||MR6, room 2501||8:30am|
|May 4th, 2021||April 22nd, 2021||MR6, room 2501||8:30am|
|June 1st, 2021||May 20th, 2021||MR6, room 2501||8:30am|
|July 6th, 2021||June 24th, 2021||MR6, room 2501||8:30am|
|August 3rd, 2021||July 22nd, 2021||MR6, room 2501||8:30am|
|September 7nd, 2021||August 26th, 2021||MR6, room 2501||8:30am|
|October 5th, 2021||September 23rd , 2021||MR6, room 2501||8:30am|
|November 4th, 2021||October 21st, 2021||MR6, room 2501||8:30am|
|December 7th, 2021||November 23rd, 2021||MR6, room 2501||8:30am|
|January 4th, 2022||December 20th, 2021||MR6, room 2501||8:30am|
Prof. Barbara J. Mann
Department of Medicine, Infectious Diseases
Associate Director of the Center for Comparative Medicine
UVA Biosafety Officer
Alternate Responsible Official (Select Agents)
Department of Medicine, Pulmonary and Critical Care
Glynis L. Kolling
Assistant Professor of Medicine
Department of Biomedical Engineering
Responsible Official (Select Agents)
Prof. Aaron L. Mills
Department of Environmental Sciences
Prof. Ira Schulman
Department of Pharmacology
Prof. Scott Vande Pol
Department of Pathology